Phase 1 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have voluntarily signed a consent form agreeing to take part in the study.
• People aged 18 to 75 years old at the time of joining.
• People whose general physical health and ability to carry out daily activities is rated as fully active or restricted only in physically strenuous activity (confirm with trial site for exact rating scale used).
• People whose life expectancy is at least 3 months.
• People who have been diagnosed with stage IVb nasopharyngeal cancer (a type of cancer at the back of the nose/throat), confirmed through a tissue or cell sample.
• People with nasopharyngeal cancer that has spread to other parts of the body, who have not yet received first-line platinum-based chemotherapy (a standard type of chemotherapy for this cancer).
• People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines.
• People whose liver, kidneys, blood, and other organs are functioning well enough to participate (confirm with trial site for specific requirements).
• Women who could become pregnant must agree to use contraception during the study and for 6 months after it ends, must have a negative pregnancy blood test within 7 days before starting, and must not be breastfeeding. Men must also agree to use contraception during the study and for 6 months after it ends.
• People who are willing and able to follow the study schedule, including attending visits, completing treatment, and undergoing required tests.

Who may not be able to join:

• People who have had another type of cancer within the past 3 years, not counting nasopharyngeal cancer. (Note: people who have had certain skin cancers, early-stage bladder cancer, or pre-invasive cervical or breast cancer that was fully treated locally may still be considered eligible — confirm with trial site.)
• People who have taken part in another clinical trial or used an experimental medical device within the 4 weeks before starting this study.
• People who received certain recent treatments before starting: local treatment to non-target tumours within the past 2 weeks; general immune-boosting therapies (such as interleukins, interferons, or thymosin) within the past 2 weeks; or certain traditional Chinese herbal or patent medicines with anti-tumour uses within the past week.
• People whose cancer got worse during, or within 6 months after, receiving treatment for locally advanced disease (such as chemotherapy before or after radiation, or combined treatment), not counting oral single-agent chemotherapy maintenance.
• People who have both a local return of cancer and spread to distant parts of the body after completing full treatment for locally advanced disease.
• People whose nasopharyngeal cancer has come back after radiotherapy and who have already had a second course of radiotherapy.
• People who have previously received any type of immunotherapy, including treatments that work on the immune system's checkpoint pathways, immune cell therapies, or similar treatments.
• People who have previously received therapy specifically targeting blood vessel growth in tumours.
• People who have other serious health conditions or circumstances that, in the treating doctor's judgement, could put them at risk or make completing the study difficult.

Important: Always verify eligibility with the trial site directly before applying.